CMTM4 and breast carcinoma: Recent studies have shown that CMTM6 combined with its family member CMTM4 can maintain the stability of PD-L1 and prevent PD-L1 from lysosome hydrolyzation in multiple tumor types, such as melanoma, breast cancer, and lung cancer [13, 14].